Diabetes

Rexinoids, TZDs Have Independent And Tissue-Specific Effects

Published in Gene Therapy Weekly, May 24th, 2001

by N.R. Saltmarsh, staff medical writer - Rexinoids and thiazolidinediones (TZDs) have different effects on metabolic gene expression in diabetic mice, say researchers working in the United States.

"We compared the effects of a rexinoid (LG100268) and a TZD (rosiglitazone) on gene expression in white adipose tissue, skeletal muscle, and liver of Zucker diabetic fatty rats," reported H.S. Ahuja and colleagues at the University of Texas Medical School in Houston.

They found that in adipose tissue, rosiglitazone decreased tumor necrosis factor-alpha (TNF-alpha) and induced glucose transporter 4 (GLUT4), muscle carnitine palmitoyl-transferase (MCPT),...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry